- Home
- AKRO vs HG Comparison
AKRO vs HG Comparison
Compare AKRO & HG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- HG
- Stock Information
- Founded
- AKRO 2017
- HG 2013
- Country
- AKRO United States
- HG Bermuda
- Employees
- AKRO N/A
- HG N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- HG
- Sector
- AKRO Health Care
- HG
- Exchange
- AKRO Nasdaq
- HG Nasdaq
- Market Cap
- AKRO 2.8B
- HG N/A
- IPO Year
- AKRO 2019
- HG 2023
- Fundamental
- Price
- AKRO $42.39
- HG $20.28
- Analyst Decision
- AKRO Strong Buy
- HG Buy
- Analyst Count
- AKRO 9
- HG 6
- Target Price
- AKRO $76.29
- HG $23.17
- AVG Volume (30 Days)
- AKRO 1.1M
- HG 470.8K
- Earning Date
- AKRO 05-16-2025
- HG 05-07-2025
- Dividend Yield
- AKRO N/A
- HG N/A
- EPS Growth
- AKRO N/A
- HG N/A
- EPS
- AKRO N/A
- HG 3.03
- Revenue
- AKRO N/A
- HG $2,443,695,000.00
- Revenue This Year
- AKRO N/A
- HG $12.17
- Revenue Next Year
- AKRO N/A
- HG $13.68
- P/E Ratio
- AKRO N/A
- HG $6.34
- Revenue Growth
- AKRO N/A
- HG 27.70
- 52 Week Low
- AKRO $17.86
- HG $14.53
- 52 Week High
- AKRO $58.40
- HG $21.68
- Technical
- Relative Strength Index (RSI)
- AKRO 52.42
- HG 63.02
- Support Level
- AKRO $41.60
- HG $18.13
- Resistance Level
- AKRO $46.47
- HG $18.72
- Average True Range (ATR)
- AKRO 2.05
- HG 0.64
- MACD
- AKRO 0.37
- HG 0.24
- Stochastic Oscillator
- AKRO 55.60
- HG 96.19
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.